Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

Journal of Neural Transmission

Volumn 121, Issue 12, 2014, Pages 1541-1553

  Tang, Wei ^a   Huang, Qiong ^a   Yao, Yu You ^a   Wang, Yan ^a   Wu, Yi Le ^a   Wang, Zheng Yu ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Dementia; Meta analysis; Mild cognitive impairment; Phosphorylated tau 181

Indexed keywords

BIOLOGICAL MARKER; TAU 181 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COCHRANE LIBRARY; DATA BASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; EMBASE; FRONTOTEMPORAL DEGENERATION; HUMAN; MEDLINE; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; SPRINGERLINK; BIBLIOGRAPHIC DATABASE; CEREBROSPINAL FLUID; FEMALE; MALE; PHOSPHORYLATION;

ALZHEIMER DISEASE; DATABASES, BIBLIOGRAPHIC; DEMENTIA; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PHOSPHORYLATION; TAU PROTEINS;

EID: 84911805539     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1226-y     Document Type: Review

References (81)

1. Alexopoulos P, Guo LH, Kratzer M et al (2011) Impact of SORL1 single nucleotide polymorphisms on Alzheimer’s disease cerebrospinal fluid markers. Dement Geriatr Cognit Disord 32:164–170
2. Apostolova LG, Hwang KS, Andrawis JP et al (2010) 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 31(8):1284–1303
3. Bibl M, Mollenhauer B, Esselmann H et al (2008) Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cognit Disord 25(3):256–265
4. Blasko I, Lederer W, Oberbauer H et al (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cognit Disord 21(1):9–15
5. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 1(2):213–225
6. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:605–613
7. Blennow K, Wallin A, Hager O (1993) Low frequency of postlumbar puncture headache in demented patients. Acta Neurol Scand 88:221–223
8. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403
9. Blom ES, Giedraitis V, Zetterberg H et al (2009) Rapid progression from mild cognitive impairment to Alzheimer’s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cognit Disord 27(5):458–464
10. Borroni B, Malinverno M, Gardoni F et al (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71(22):1796–1803
11. Borroni B, Gardoni F, Parnetti L et al (2009) Pattern of tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 30:34–40
12. Bouwman FH, van der Flier WM, Schoonenboom NS et al (2007) Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69(10):1006–1011
13. Chui HC, Victoroff JI, Margolin D et al (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 42:473–480
14. Cohen J (1992) A power primer. Psychol Bull 112:155–159
15. Cummings JL (1988) Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1(1):24–36
16. de Jong D, Jansen RW, Kremer BP, Verbeek MM (2006) Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61(7):755–758
17. Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2(4):229–237
18. Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707
19. Engelborghs S, Maertens K, Vloeberghs E et al (2006) Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem Int 48:286–295
20. Exalto LG, van der Flier WM, Scheltens P, Biessels GJ (2010) Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic. J Am Geriatr Soc 58(7):1318–1321
21. Frank RA, Galasko D, Hampel H et al (2003) Biological markers for therapeutic trials in Alzheimer’s disease. Neurobiol Aging 24(4):521–536
22. Gabelle A, Roche S, Gény C et al (2011) Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis 26(3):553–563
23. Galimberti D, Venturelli E, Fenoglio C et al (2008) Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer’s disease and frontotemporal lobar degeneration. J Neurol 255:539–544
24. Habert MO, de Souza LC, Lamari F et al (2010) Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 37(3):589–593
25. Hampel H, Mitchell A, Blennow K et al (2004) Core biological marker candidates of Alzheimer’s disease—perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 111:247–272
26. Hampel H, Blennow K, Shaw LM et al (2010) Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 45:30–40
27. Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228–234
28. Henneman WJ, Vrenken H, Barnes J et al (2009) Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73(12):935–940
29. Herbert MK, Aerts MB, Kuiperij HB et al (2013) Addition of MHPG to Alzheimer’s disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer’s disease but not other dementias. Alzheimers Dement. doi:10.1016/j.jalz.2013.05.1775
30. Ibach B, Binder H, Dragon M et al (2006) Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 27(9):1202–1211
31. Irwin DJ, White MT, Toledo JB et al (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587–598
32. Jagust WJ, Landau SM, Shaw LM et al (2009) Relationships between biomarkers in aging and dementia. Neurology 73(15):1193–1199
33. Jellinger KA (1996) Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol 91:219–220
34. Jellinger KA (2009) Formation and development of Lewy pathology: a critical update. J Neurol 256(Suppl 3):270–279
35. Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115(4):427–436
36. Jia JP, Meng R, Sun YX et al (2005) Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer’s disease and vascular dementia. Neurosci Lett 383:12–16
37. Jicha GA, Abner EL, Schmitt FA (2012) Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33(3):622.e1–622.e16
38. Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM (2012) Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer’s disease. Methods 56(4):484–493
39. Kasuga K, Tokutake T, Ishikawa A et al (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 81(6):608–610
40. Lanari A, Parnetti L (2009) Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting. Sci World J 9:961–966
41. Le Bastard N, Van Buggenhout M, De Leenheir E et al (2007) Low specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate Alzheimer’s disease from vascular dementia. J Gerontol A Biol Sci Med Sci 62:923–924
42. Lewczuk P, Beck G, Ganslandt O et al (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409:1–4
43. Mackenzie IR, Foti D, Woulfe J, Hurwitz TA (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131:1282–1293
44. McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124
45. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872
46. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944
47. Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80:966–975
48. Mollenhauer B, Bibl M, Wiltfang J et al (2006) Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1–40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 44(2):192–195
49. Mouton-Liger F, Paquet C, Dumurgier J et al (2012) Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer’s disease. Biol Psychiatry 71:829–835
50. Mulugeta E, Londos E, Ballard C et al (2011) CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 82(2):160–164
51. Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554
52. Nettiksimmons J, Harvey D, Brewer J et al (2010) Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging 31(8):1419–1428
53. Noguchi-Shinohara M, Tokuda T, Yoshita M et al (2009) CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer’s disease. Brain Res 1251:1–6
54. Okonkwo OC, Alosco ML, Griffith HR et al (2010) Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol 67(6):688–696
55. Parnetti L, Lanari A, Silvestrelli G et al (2006) Diagnosing prodromal Alzheimer’s disease: role of CSF biochemical markers. Mech Ageing Dev 127(2):129–132
56. Parnetti L, Tiraboschi P, Lanari A et al (2008) Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64(10):850–855
57. Randall C, Mosconi L, de Leon M et al (2013) Cerebrospinal fluid biomarkers of Alzheimer’s disease in healthy elderly. Front Biosci 18:1150–1173
58. Ravaglia S, Bini P, Sinforiani E et al (2008) Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia. Neurol Sci 29:417–423
59. Regeniter A, Kuhle J, Baumann T et al (2012) Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. Methods 56(4):494–499
60. Riepe MW, Karl J, Tumani H, von Arnim CA (2010) Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment. Dement Geriatr Cognit Disord 30(2):93–100
61. Roman GC, Tatemichi TK, Erkinjutti T et al (1993) Vascular dementia: diagnostic criteria for research studies-report of the NINDSAIREN International Workshop. Neurology 43(2):250–260
62. Schmand B, Eikelenboom P, van Gool WA et al (2011) Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer’s disease in younger and older age cohorts. J Am Geriatr Soc 59(9):1705–1710
63. Schott JM, Bartlett JW, Barnes J et al (2010) Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiol Aging 31(8):1452–1462
64. Seppälä TT, Koivisto AM, Hartikainen P et al (2011) Longitudinal changes of CSF biomarkers in Alzheimer’s disease. J Alzheimers Dis 25(4):583–594
65. Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65(4):403–413
66. Sjögren M, Davidsson P, Tullberg M et al (2001) Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 70:624–630
67. Sjögren M, Davidsson P, Wallin A et al (2002) Decreased CSF-beta-amyloid 42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta amyloid induced by disparate mechanisms. Dement Geriatr Cognit Disord 13:112–118
68. Sluimer JD, Bouwman FH, Vrenken H et al (2010) Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 31(5):758–764
69. Solé-Padullés C, Lladó A, Bartrés-Faz D et al (2011) Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer’s disease continuum. Psychiatry Res 192(3):140–146
70. Spies PE, Slats D, Sjögren JM et al (2010) The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer’s disease from non-Alzheimer’s dementia. Curr Alzheimer Res 7(5):470–476
71. Sundelöf J, Sundström J, Hansson O et al (2010) Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer’s disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis 21(2):471–478
72. Thorsell A, Bjerke M, Gobom J et al (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res 1362:13–22
73. Tomlinson BE, Blessed G, Roth M (1970) Observations on brains of demented old people. J Neurol Sci 11:205–242
74. Tosun D, Schuff N, Truran-Sacrey D et al (2010) Relations between brain tissue loss, CSF biomarkers and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging 31(8):1340–1354
75. van der Flier WM, Scheltens P (2005) Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 76(Suppl 5):v2–v7
76. van Harten AC, Kester MI, Visser PJ et al (2011) Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 49(3):353–366
77. Verwey NA, Kester MI, van der Flier WM et al (2010) Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 20(2):445–452
78. Wada-Isoe K, Kitayama M, Nakaso K et al (2007) Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 260:33–37
79. Waldemar G, Dubois B, Emre M et al (2007) Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14:e1–e26
80. Wennström M, Londos E, Minthon L et al (2012) Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis 29(1):125–132
81. Westin K, Buchhave P, Nielsen H et al (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One 7(1):e30525